

- (3) None.  
(4) None.

This statement is made as of February 2, 1972.

Dated: February 2, 1972.

LEROY J. SCHULTZ.

[FR Doc.72-4173 Filed 3-17-72;8:48 am]

### WILLARD B. SIMONDS

#### Statement of Changes in Financial Interests

In accordance with the requirements of section 710(b) (6) of the Defense Production Act of 1950, as amended, and Executive Order 10647 of November 28, 1955, the following changes have taken place in my financial interests during the past 6 months:

- (1) No change.  
(2) No change.  
(3) No change.  
(4) No change.

This statement is made as of January.

Dated: January 31, 1972.

WILLIAM B. SIMONDS.

[FR Doc.72-4174 Filed 3-17-72;8:48 am]

### STANLEY M. SWANSON

#### Statement of Changes in Financial Interests

In accordance with the requirements of section 710(b) (6) of the Defense Production Act of 1950, as amended, and Executive Order 10647 of November 28, 1955, the following changes have taken place in my financial interests during the past 6 months:

- (1) No change.  
(2) No change.  
(3) No change.  
(4) No change.

This statement is made as of March 6, 1972.

Dated: March 6, 1972.

STANLEY M. SWANSON.

[FR Doc.72-4175 Filed 3-17-72;8:48 am]

### CHARLES W. WATSON

#### Statement of Changes in Financial Interests

In accordance with the requirements of section 710(b) (6) of the Defense Production Act of 1950, as amended, and Executive Order 10647 of November 28, 1955, the following changes have taken place in my financial interests during the past 6 months:

- (1) No change.  
(2) No change.  
(3) No change.  
(4) No change.

This statement is made as of February 1, 1972.

Dated: February 1, 1972.

CHARLES W. WATSON.

[FR Doc.72-4176 Filed 3-17-72;8:48 am]

## DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

### Food and Drug Administration

#### AMERICAN CYANAMID CO.

#### Notice of Filing of Petition for Food Additive

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 409 (b) (5), 72 Stat. 1786; 21 U.S.C. 348(b) (5)), notice is given that a petition (FAP 2B2763) has been filed by American Cyanamid Co., Wayne, N.J. 07470 proposing that § 121.2571 *Components of paper and paperboard in contact with dry food* (21 CFR 121.2571) be amended to provide for the safe use of acrylamide, N-(dimethylaminemethyl) acrylamide, styrene terpolymer as a dry-strength agent in paper and paperboard intended for contact with dry food.

Dated: March 10, 1972.

VIRGIL O. WODICKA,  
Director, Bureau of Foods.

[FR Doc.72-4146 Filed 3-17-72;8:45 am]

[Docket No. FDC-D-362; NDA 11-253, etc.]

### CERTAIN DRUGS CONTAINING VALETHAMATE BROMIDE

#### Notice of Withdrawal of Approval of New Drug Applications

A notice was published in the FEDERAL REGISTER of October 9, 1971 (36 F.R. 19710), extending to Ayerst Laboratories, Division of American Home Products Corp., 685 Third Avenue, New York, NY 10017, and to any interested person who may be adversely affected, an opportunity for hearing on the proposal of the Commissioner of Food and Drugs to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act, withdrawing approval of the following new-drug applications and all amendments and supplements thereto. The basis of the proposed action was the lack of substantial evidence that the drugs are effective for their labeled indications. The drugs are no longer marketed.

NDA 11-253; Murel Tablets containing valethamate bromide.

NDA 11-989; Murel S.A. Tablets containing valethamate bromide.

NDA 11-290; Murel with Phenobarbital Tablets containing valethamate bromide and phenobarbital.

NDA 11-998; Murel with Phenobarbital S.A. Tablets containing valethamate bromide and phenobarbital.

NDA 11-263; Murel Injection containing valethamate bromide.

Neither the holder of the new-drug applications nor any other interested person have filed a written appearance of election as provided by said notice. The failure to file such an appearance is construed as an election by such persons not to avail themselves of an opportunity for hearing.

The Commissioner of Food and Drugs, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act 505(e), 52 Stat. 1053, as amended; 21 U.S.C. 355(e) and under authority delegated to him (21 CFR 2.120), finds that on the basis of new information before him with respect to each of said drugs, evaluated together with the evidence available to him when each application was approved, there is a lack of substantial evidence that each of the drugs will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling thereof.

Therefore, pursuant to the foregoing finding, approval of the above-listed new-drug applications and all amendments and supplements thereto is withdrawn effective on the date of publication hereof in the FEDERAL REGISTER (3-18-72).

Dated: March 10, 1972.

SAM D. FINE,  
Associate Commissioner  
for Compliance.

[FR Doc.72-4147 Filed 3-17-72;8:45 am]

[Docket No. FDC-D-445, NDA 0-723, etc.]

### S. E. MASSENGILL CO., ET AL.

#### New-Drug Applications; Notice of Withdrawal of Approval

The holders of the new-drug applications listed herein have not submitted annual reports of experience with the drugs as required and have advised the Food and Drug Administration that the new drugs involved were never marketed or marketing has been discontinued and have requested withdrawal of approval of the new-drug applications, thereby waiving opportunity for a hearing.

Therefore pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505(e), 52 Stat. 1053, as amended; 21 U.S.C. 355(e)), and under authority delegated to the Commissioner (21 CFR 2.120), approval of the following new-drug applications, including all amendments and supplements thereto, is hereby withdrawn on the grounds that the applicants have failed to make reports under section 505(j) of the Act (21 U.S.C. 355(j) and §§ 130.13 and 130.35 (e) and (f) of the new-drug regulations (21 CFR 130.13 and 130.35).